We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia. This decision represents a significant advance in the application of the law relating to induced infringement.